Drug intelligence / Profile preview

NSA-789

Development stage: Phase 1
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

NSA-789 is an orally administered small molecule drug that was developed by Wyeth and later Pfizer for the treatment of cognitive impairment associated with Alzheimer's disease and schizophrenia. It was classified as both an antidementia and antipsychotic agent, but its precise mechanism of action remains undefined. The drug reached Phase 1 clinical trials for both Alzheimer's disease and schizophrenia, including studies in healthy volunteers, but development was discontinued after these early-stage trials[1][2][3]. No orphan drug status or FDA approval was granted.

Other names: NSA 789NSA789NSA-789

Beyond the preview

Go deeper on NSA-789.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NSA-789.

Explore the full profile